Key regulators of sensitivity to immunomodulatory drugs in cancer treatment

Shichao Wang\textsuperscript{1*}, Zhiyue Li\textsuperscript{2} and Shaobing Gao\textsuperscript{2*}

Abstract

Immunomodulatory drugs (IMiDs) include thalidomide, lenalidomide, and pomalidomide, which have shown significant efficacy in the treatment of multiple myeloma (MM), myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) and other hematological malignancies. IMiDs hijack the CRL4\textsuperscript{CRBN} ubiquitin ligase to target cellular proteins for ubiquitination and degradation, which is responsible for their clinical activity in MM and MDS with del(5q). However, intrinsic and acquired resistance frequently limit the efficacy of IMiDs. Recently, many efforts have been made to explore key regulators of IMiD sensitivity, resulting in great advances in the understanding of the regulatory networks related to this class of drugs. In this review, we describe the mechanism of IMiDs in cancer treatment and summarize the key regulators of IMiD sensitivity. Furthermore, we introduce genome-wide CRISPR-Cas9 screenings, through which the regulatory networks of IMiD sensitivity could be identified.

Keywords: Immunomodulatory drugs, CRISPR-Cas9 screening, CRL4\textsuperscript{CRBN} E3 ligase, PROTACs, Multiple myeloma, Ubiquitination, CC-90009

Background

Thalidomide and its derivatives lenalidomide and pomalidomide are often called immunomodulatory drugs (IMiDs) due to their modulatory effects on immune cells [1–4]. IMiDs have shown remarkable therapeutic efficacy in several hematological malignancies. In combination with steroids, proteasome inhibitors and monoclonal antibodies, IMiDs are widely used to treat multiple myeloma (MM) [5–9]. Lenalidomide also has therapeutic activity in myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) [10, 11], mantle cell lymphoma (MCL) [12–15] and chronic lymphocytic leukemia (CLL) [16–18]. New generations of IMiDs, including CC-122 (avadomide) [19–22], CC-220 (iberdomide) [23, 24], CC-885 [25, 26], CC-92480 [27] and CC-90009 [28] (Fig. 1), are being evaluated for their potential to treat diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), MM and acute myeloid leukemia (AML) [29, 30].

Although IMiDs have shown significant efficacy in a range of hematological malignancies, primary and acquired drug resistance limit their clinical application. Thus, it is necessary to delineate the regulatory networks related to IMiD sensitivity. Recently, emerging evidence has shown that sensitivity to IMiDs is regulated by several factors, including CRBN, the Cullin-RING ligase 4 (CRL4) E3 ubiquitin ligase [31–34], RUNX proteins [35], and Wnt/β-Catenin pathway members [36]. Moreover, genome-scale CRISPR screenings have identified a series of key regulators of sensitivity to IMiDs [37–41].

In this review, we highlight the underlying mechanisms of IMiDs in cancer treatment and summarize the key regulators of IMiD sensitivity. Furthermore, we
introduce genome-wide CRISPR screenings as a tool that can identify regulatory networks of IMiD sensitivity.

**Mechanism of IMiD activity**

CRBN, the primary cellular target of IMiDs [42], is a substrate receptor of CRL4, an E3 ubiquitin ligase complex consisting of Cullin 4 A/4B, DNA damage-binding protein 1 (DDB1) and a small RING protein (RBX) [43]. IMiDs hijack the CRL4\(^{CRBN}\) E3 ligase to ubiquitinate and degrade two essential lymphoid transcription factors, IKZF1 (Ikaros) and IKZF3 (Aiolos), which leads to the downregulation of IRF4 and MYC, resulting in the toxicity of MM cells [44, 45]. Lenalidomide can bind the CRL4\(^{CRBN}\) E3 ligase to induce ubiquitination and degradation of CK1\(^{\alpha}\), accounting for its efficacy in del(5q) MDS [46]. A number of other neosubstrates of IMiDs have been identified using proteomics analysis [47, 48]. Furthermore, the degradation of SALL4, PLZF and P63 proteins was reported to be correlated with thalidomide-induced malformations [48–51]. Thus, this class of compounds are also called CRBN E3 ligase modulators (CELMoDs). IMiDs represent the first class of drugs that function by inducing the degradation of cellular proteins (Fig. 2), which has important implications for the design of novel therapeutic compounds.

**Overview of emerging regulators of sensitivity to immunomodulatory drugs**

Since IMiDs bind the CRL4\(^{CRBN}\) E3 ligase to ubiquitinate and degrade disease-related proteins, the components of the CRL4\(^{CRBN}\) E3 ligase and its activity are hypothesized to be essential for the antitumor activity of IMiDs. Recently, emerging evidence has shown the significance of CRL4\(^{CRBN}\) components for IMiD sensitivity, together with other cellular molecules and pathways.
CRBN
As the primary target of IMiDs, CRBN was reported to be essential for the activity of IMiDs. CRBN knockdown leads to resistance to lenalidomide and pomalidomide in MM cell lines [31]. In addition, lenalidomide- or pomalidomide-resistant MM cells generated by incubation with gradually increasing concentrations of lenalidomide/pomalidomide show a significant decrease in CRBN protein levels [31, 52], suggesting an important role of CRBN in acquired IMiD resistance.

According to several clinical observations, high expression of CRBN has been reported to correlate with improved clinical response to IMiDs in MM patients [32, 33]. In addition, targeted sequencing data have shown that MM patients resistant to IMiDs frequently harbor CRBN mutations [53]. CRBN alterations, including point mutations, copy loss/structural variations and an exon 10 splice variant transcript, have been found in lenalidomide- or pomalidomide-resistant MM patients [54]. Moreover, approximately one-third of MM patients who are refractory to pomalidomide are reported to carry genetic alterations in CRBN [54].

High expression of CRBN is associated with increased clinical efficacy of lenalidomide in del(5q) MDS, while a decrease in CRBN expression correlates with loss of response and disease progression [55]. CRBN expression can also predict clinical response in CLL patients treated with IMiD-based therapy [56].

The above evidence indicates that CRBN expression is required for the antitumor activity of IMiDs. However, a lack of CRBN mutations or downregulation of CRBN expression levels has been reported in three MM cell lines intrinsically resistant to IMiDs [57]. In addition, a study reported that only one out of five MM patients refractory to lenalidomide showed significantly low expression of CRBN before treatment [58], indicating that factors other than CRBN might regulate intrinsic resistance to IMiDs.

CRL4 and IKZF1/3
As IMiDs function through hijacking CRL4CRBN E3 ligase to target neosubstrates like IKZF1/3 for ubiquitination and degradation, the expression of these components is supposed to be a necessity. Cullin 4 proteins consist of two homogenous members, Cullin 4A and Cullin 4B, which serve as scaffolds for the CRL4E3 ligase [43]. Mounting evidence has shown that Cullin 4A and Cullin 4B proteins can promote tumorigenesis in a number of malignancies [59–62]. Overexpression of Cullin 4A in thalidomide-resistant prostate cancer cells can restore sensitivity to thalidomide, while knockdown of this gene in thalidomide-sensitive 22RV1 cells leads to drug resistance [34]. In addition, mutations in Cullin 4B have been found in MM cases with acquired IMiD resistance, as have mutations in CRBN, DDB1 and IKZF1/3 [63].

IKZF1 (Q146H) and IKZF3 (Q147H) mutants are resistant to lenalidomide-induced degradation, and overexpression of either mutant protein can cause resistance to lenalidomide in MM1S cells [44, 45]. IKZF1 expression is decreased in IMiD-resistant MM cell lines, while MM patients with low expression of IKZF1 show a lack of response to IMiD treatment with shorter overall survival than patients with high expression of IKZF1 [64, 65]. IKZF3 expression predicts favorable response to lenalidomide and high expression of IKZF1/3 is correlated with longer median progression free survival in MM [66]. Moreover, alterations in IKZF3 at diagnosis have been reported, suggesting that IKZF3 mutations may contribute to the pathogenesis of MM [63].

RUNX proteins
The RUNX family of transcription factors, composed of RUNX1, RUNX2 and RUNX3, are highly conserved and form heterodimers with CBFB to regulate target gene expression during development and hematopoiesis [67–70]. Aberrations in RUNX have been frequently identified in leukemia and solid tumors [71–74]. Recently, RUNX proteins have been found to interact and protect IKZF1 and IKZF3 proteins from lenalidomide-induced ubiquitination and degradation, resulting in the desensitization of MM cells to lenalidomide. Inhibition of RUNX proteins by the small molecule AI-10-104 leads to sensitization to lenalidomide in MM cell lines and primary MM cells [35], providing a reference for the combined use of RUNX inhibitors and IMiDs in MM treatment.

In contrast, loss of function of RUNX1 causes lenalidomide resistance in del(5q) MDS cells, suggesting that RUNX1 function is required for lenalidomide sensitivity [75, 76]. Recurrent variants of RUNX1 have been discovered in del(5q) MDS patients who become resistant to lenalidomide. Furthermore, RUNX1 forms a complex with GATA2 to drive megakaryocytic differentiation, which is required for lenalidomide efficacy [75]. Thus, RUNX proteins seem to have contrasting impacts on lenalidomide sensitivity in MM and del(5q) MDS cells.

MEK/ERK
Ras/RAF/MEK/ERK (mitogen-activated protein kinase, MAPK) signaling regulates cellular proliferation, differentiation and survival. Aberrant activation of the MAPK pathway is frequently observed in human cancers, and small molecules targeting this pathway have been approved to treat cancers, including melanoma, colorectal cancer and non-small-cell lung cancer [77, 78]. In a xenograft MM mouse model, acquired resistance to lenalidomide and pomalidomide is developed by continuous administration of pomalidomide-dexamethasone (PD), lenalidomide-dexamethasone (LD) or vehicle [79].
Upregulation of the MEK/ERK pathway has been found in IMiD-resistant cells, whose sensitivity to lenalidomide or pomalidomide can be restored by selumetinib, a small molecule MEK inhibitor [79].

**Wnt/β-catenin signaling**

The conserved Wnt/β-catenin signaling pathway is a key regulator of development, the dysregulation of which is involved in tumorigenesis [80, 81]. Targeting Wnt/β-catenin signaling has been proposed to improve the efficacy of cancer immunotherapy [82]. Dysregulation of Wnt/β-catenin signaling was identified in a lenalidomide-resistant MM cell line [36]. Stimulation of the Wnt/β-catenin pathway can reduce the antitymoma activity of lenalidomide, while inhibition of β-catenin can restore sensitivity to lenalidomide [36]. This evidence suggests the possibility of targeting Wnt/β-catenin signaling with inhibitors to alleviate IMiD resistance.

**Other factors**

Sensitivity to IMiDs has been reported to be affected by factors other than those discussed above. In IMiD-resistant MM cells, dysregulation of a number of signaling mediators has been identified, including upregulation of IL-6/activation of STAT3 [83], increased genome-wide DNA methylation [84], dysregulation of HIF-1α [85, 86], dysregulation of CD44 [87], and decreased CD138 levels [88]. In addition, cellular antioxidative capacity can also affect sensitivity to lenalidomide in MM cells [89]. Activation of c-Abl kinase can potentiate the antitymoma activity of lenalidomide [90]. RNAi and shRNA screenings have revealed that ribosomal protein S6 kinase (RSK2) and karyopherin beta 1 (KPNB1) are required for IMiD sensitivity in MM cells [89]. In one CRISPR-Cas9 screen, a library of sgRNAs targeting genes essential for IMiD sensitivity in MM, primary effusion lymphoma (PEL) and AML [37–39].

**Genome-wide CRISPR screenings as a tool to identify genes required for IMiD sensitivity**

**CRISPR genome editing and application**

The CRISPR-Cas system, derived from the prokaryotic adaptive immune system, has been modified to be a powerful tool in targeted genome editing [97–99]. CRISPR-Cas9 genome editing is now widely used to generate gene-engineered cell lines and animals in laboratories worldwide [97, 98, 100]. Furthermore, CRISPR-mediated knockout of TCR and HLA class I molecules contributes to the generation of universal CAR-T cells [101–104]. Recent attempts have been made to use the CRISPR-Cas system therapeutically, especially in genetic disorders related to single gene mutations, including sickle cell anemia, cystic fibrosis and Huntington’s chorea [105, 106].

In addition to its utility for research on single gene modifications, the CRISPR-Cas system has been applied for large-scale functional screening in genomic, transcriptomic or epigenetic research [107–110]. Genome-wide CRISPR-Cas9 screening has been established to search for critical genes involved in drug resistance (Fig. 3a) [107]. Recently, genome-scale CRISPR screenings have been carried out to identify essential genes required for IMiD sensitivity in MM, primary effusion lymphoma (PEL) and AML [37–39].

**CRISPR-Cas9 screenings to identify genes required for IMiD sensitivity**

In one CRISPR-Cas9 screen, a library of sgRNAs targeting 19,050 genes and 1,000 control sgRNAs were introduced into MM1S cells, which were then incubated with lenalidomide or DMSO. Then, these cells were collected and analyzed using next-generation sequencing to identify genes required for IMiD activity in MM cells [37]. Among the top 30 genes, 17 were related to CRL4 E3 ligases, including CRBN, DDB1, subunits of the COP9 signalosome (CSN), CAND1, UBE2G1 and UBE2D3 [37]. In another CRISPR-Cas9 screen to identify genes required for pomalidomide activity in MM1S cells, a similar subset of targets was discovered [38]. The genes essential for IMiD activity in MM cells are summarized in Fig. 3b.

IMiDs have shown significant efficacy in PEL, a non-Hodgkin B cell lymphoma [111, 112]. A CRISPR-Cas9 screen was conducted in PEL cells to search for genes essential for the activities of lenalidomide, pomalidomide and CC-122 [39]. According to the results, components of the CRL4 machinery were again identified, including CRBN, Cullin 4 A/4B, UBE2G1 and SENP8, together with other targets [39].

CC-90009, a new CRBN modulator, has shown notable efficacy in AML by selectively inducing degradation of GSPT1. CC-90009 promotes apoptosis of leukemia stem
Cells in xenografting of 35 primary AML samples, regardless of the adverse risk features [28]. Based on the promising efficacy, CC-90009 has entered clinical trials for AML and MDS (Table 1). A CRISPR-Cas9 screen in U937 cells has revealed essential genes for the efficacy of CC-90009, including subunits of CRL4 CRBN E3 ligase, CSN, CAND1, ILF2/ILF3 [28].

In summary, components of the CRL4 E3 ligase are required for IMiD sensitivity, which is consistent with the mechanism of these compounds. Furthermore, regulators of CRL4 E3 ligase activity for example, CSN, also affect IMiD activity. Deletion of CSN causes a significant decrease in CRBN protein levels in MM cells, which can explain the IMiD resistance in CSN-deleted cells [38]. AT-rich interactive domain 2 (ARID2), a component of the polybromo-BRG1-associated factors (PBAF) chromatin-remodeling complex, was also identified to be required for pomalidomide activity in MM cells [38], which was recently verified by the discovery of ARID2 as a pomalidomide-induced neosubstrate [113]. Degradation of ARID2 causes downregulation of MYC, leading to the death of MM cells [113]. These data demonstrate the powerful function of CRISPR screens in the discovery of regulatory networks of drug sensitivity.

**Conclusion and perspective**

As the primary target of IMiDs, CRBN is required for IMiD sensitivity. Due to the rapid development of biotechnology tools such as CRISPR genome editing, many other regulators of IMiD sensitivity have been identified. CRL4 components such as Cullin 4 A/4B, DDB1 and E2 and regulators of E3 ligase are also required for IMiD sensitivity. Degradation of IKZF1/3 are essential for antimyeloma activity of IMiDs in MM. RUNX1 and GATA2 are required for lenalidomide activity in del(5q) MDS. Mutations in components of CRL4 CRBN E3 ligase, mainly CRBN itself, IKZF1/3 and RUNX have been identified in IMiD-resistant cells, together with dysregulation of

**Table 1** Clinical trials of CC-90009

| Phase | Conditions | Interventions | NCT ID |
|-------|------------|---------------|--------|
| 1     | Healthy Volunteer | CC-90009, Radiation: [14 C] | NCT04297124 |
| 1     | AML, MDS | CC-90009 | NCT02848001 |
| 1, 2  | AML | CC-90009, Venetoclax, Azacitidine, Gilteritinib | NCT04336982 |

_Abbreviation: AML acute myeloid leukemia, MDS myelodysplastic syndrome_
MEK/ERK, Wnt/β-catenin and IL-6/STAT3 pathways (Fig. 4). As IMiDs have also shown notable efficacy in different hematological malignancies such as CLL, DLBCL and AML, which have diverse genetic features, disease-specific regulators of IMiD sensitivity might be identified by future studies.

New generation of IMiDs are under clinical development. CC-122 is now in phase 1/2 trials for hematological malignancies, including DLBCL and MM [29]. The most common treatment-emergent adverse events (TEAEs) are neutropenia, thrombocytopenia and anemia [21, 22, 114–116]. CC-220 has shown significant efficacy in systemic lupus erythematosus (SLE) and relapsed/refractory MM (RRMM) and now under phase 1/2 studies [24, 117]. Neutropenia, infection and thrombocytopenia have been reported following CC-220 administration [118–120]. CC-92480 can induce deeper degradation of IKZF1/3, showing therapeutic advantage in lenalidomide-resistant MM cells with little effect on the viability of normal peripheral blood mononuclear cells [27]. CC-92480 is now under phase 1/2 clinical trials mainly for MM. CC-885 has anti-proliferation activity in a broad range of tumor cell lines and significant anti-AML potency by the degradation of GSPT1 [25]. CC-90009 induces the degradation of GSPT1 with higher selectivity and now in phase 1/2 clinical studies for AML and MDS. As these CRBN modulators function through a similar mechanism, the understanding of regulatory networks of IMiD sensitivity may provide reference for the development of new IMiDs.

Proteolysis-targeting chimeras (PROTACs) are bifunctional molecules that can target proteins for degradation via the ubiquitin-proteasome pathway. A typical PROTAC molecule contains a ligand for the protein of interest covalently linked to a moiety of an E3 ubiquitin RING ligase 4; CRL4: Cullin-4; CRBN: Cereblon; CSN: COP9 signalosome; E3: E3 ubiquitin ligase; E3 ligase; E3 ligase to ubiquitinate and degrade a number of cellular proteins, these molecules have been frequently used in the design of PROTACs. In this way, IMiDs have been linked to ligands of BTK, BCR-Abl, BRD4 and other targets to generate PROTACs that can degrade these oncoproteins [125–127]. Targeting protein for degradation by PROTACs has emerged as a powerful therapeutic strategy in cancer treatment. The discovery of mechanism of IMiDs facilitates the development of PROTACs by providing more choices on E3 ligase utilization. Thus, the delineation of key regulators of IMiD sensitivity may promote the development of IMiD-based PROTACs.

Abbreviations
AML: Acute myeloid leukemia; BRD4: Bromodomain-containing protein 4; ARID2: AT-rich interactive domain 2; BTK: Bruton’s tyrosine kinase; CELMoDs: CRBN E3 ligase modulators; CSN: COP9 signalosome; CRL4: Cullin-RING ligase 4; DLBCL: Diffuse large B-cell lymphoma; FL: Follicular lymphoma; GPR68: G protein-coupled receptor 68; IMiDs: Immunomodulatory drugs; KPNB1: Karyopherin beta 1; MCL: Mantle cell lymphoma; MDS: Myelodysplastic syndrome; MM: Multiple myeloma; PEL: Primary effusion lymphoma; PROTACs: Proteolysis-targeting chimeras; RRMM: Relapsed/refractory MM; RSK2: Ribosomal protein S6 kinase; SLE: Systemic lupus erythematosus; TEAEs: Treatment-emergent adverse events; VHL: Von Hippel-Lindau

Acknowledgements
Not applicable.

Authors’ contributions
SW and SG conceived, drafted and revised the manuscript. ZL prepared figure 1. All authors read and approved the final manuscript.

Funding
The study was supported by the National Natural Science Foundation of China (No. 81800204) and Medical Science and Technology Foundation of Henan Province (No. LHGJ20200178).

Availability of data and materials
The material supporting the conclusion of this review has been included within the article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 15 March 2021 Accepted: 18 May 2021
Published online: 05 June 2021

References
1. Sampao EP. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699–703.
2. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380–6.
3. Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneekarn N, Vongchan P, Corral LG, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15(13):1169–79.
4. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210–6.
42. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Immura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5970):1345–50.
43. Jackson S, Xiong Y, CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci. 2009;34(11):562–70.
44. Lu G, Middleton RE, Sun H, Naniong M, Ott CI, Mistsias CS, Wong KK, Bradner JE, Kaelin WG, Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305–9.
45. Konke J, Udeshi ND, Nafla A, Grauman P, Hurst SN, McConkey M, Sinikova T, Hechl D, Comer E, Li X, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–5.
46. Konke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, et al. Lenalidomide induces ubiquitination and degradation of Cdkalp in del(5q) MDS. Nature. 2015; 253(7309):183–8.
47. Severs QL, Peltzold G, Bunker RD, Renville A, Slabicki M, Liddicoat BJ, Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, et al. Lenalidomide induces ubiquitination and degradation of Cdkalp in del(5q) MDS. Nature. 2015;253(7309):183–8.
48. Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, Ebert BL, Fischer ES. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018; 7. https://doi.org/10.7554/eLife.38430.
49. Matskiewa ME, Couto S, Zheng X, Lu G, Hui J, Stamp K, Drew C, Ren Y, Wang M, Carpenter A. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat Chem Biol. 2018;14(10):981–7.
50. Donovon KA, Brinkley BL, Cheung SW, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Immura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5970):1345–50.
51. Tachita T, Kinoshiha S, Hi M, Aoki S, Amano A, Kanamori T, Yuhsuha T, Sato T, Shimizu N, Atakawa Y, Yamanaka Y, Ito T, Guerrini L, et al. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur J Hematol. 2015;94(3):270–72.
52. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31.
53. Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H, Li Q, He H, Shang Y, Gong Y, et al. CRL4E6 promotes tumorigenesis by coordinating with 53BP1/RNF168/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene. 2015; 34(11):104–18.
54. Barrio S, Munawar U, Zhao YX, Giesen N, Shi CX, Via MD, Sanchez R, Bruns L, Demler T, Muller N, et al. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020;105(5):1327–34.
55. Zhu YX, Braggio E, Shi C, Kortuem KM, Bruns L, Schmidt ME, Chang XB, Langlais P, Luo M, Jedlowski P, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536–45.
56. Wang B, Tian T, Kalland KH, Ke X, Qu Y. Targeting Wnt/beta-Catenin Signaling for Cancer Immunotherapy. Trends Pharmacol Sci. 2018;39(7): 649–58.
83. Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, Ahmann JM, de Campos CB, Braggio E, Bergsal PL, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF-4. Blood Cancer J. 2019;9(2):19.

84. Dimopoulos K, Sogaard Helbo A, Fibiger Munch-Petersen H, Sjo L, Christensen J, Sommer Kristensen L, Asmtr F, Hermansen NE, O'Connel C, Gimsing P, et al. Dual inhibition of DNM2 and E2H2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol. 2018;12(2):180–95.

85. Ria R, Catacchio I, Berardi S, De Luisi A, Calvano A, Piccillo C, Ruggieri V, Frassanito MA, Ristiti D, Nico B, et al. HIF-1alpha of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res. 2014;20(4):847–58.

86. Storti P, Toscani D, Airoldi I, Marchica V, Maliga S, Bolzoni M, Fiorenti E, Campanini N, Martella E, Mancini C, et al. The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)–alpha inhibition in myeloma cells. Haematologica. 2016;101(3):107–10.

87. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiate I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014;28(2):373–83.

88. Kawano Y, Fujisawa S, Wada N, Iizaka M, Yuki H, Okuno Y, Iyama K, Yamashita H, Sakai A, Mitsuya H, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012;41(3):876–84.

89. Sebastian S, Zhu YX, Braggio E, Shi CX, Panchalabi SC, Van Wier SA, Ahmann JM, Chesi M, Bergsal PL, Stewart AK, et al. Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity. Blood. 2017;129(9):1001–9.

90. Gao S, Geng C, Song T, Lin X, Liu J, Cai Z, Yang Y. Activation of c-Ab1 Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase. J Biol Chem. 2017;292(9):3683–91.

91. Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola F, et al. Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase. J Biol Chem. 2017;292(9):3683–91.

92. An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA, Fischer ES. Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon C, Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola F, et al. Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase. J Biol Chem. 2017;292(9):3683–91.

93. Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, Scott DA, Dong J, Pan JQ, Weissleder R, et al. Genome-wide HIF screening in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246–60.

94. Konermann S, Briggs MD, Trevino AE, Joung J, Abudayeh OO, Barbas C, Huub N, Habib N, Gootenberg JS, Nishimasu H, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517(7536):583–8.

95. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017;16(2):89–100.

96. Gopalarakrishnan R, Matta H, Taioli B, Trich T, Jr, Chaudhry PM. Immunomodulatory drugs target KZF1-IRF-4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016;35(14):1797–810.

97. Patil A, Manzano M, Grottwein E. Ck1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018;132(6):577–86.

98. Yamamoto J, Suwa T, Murase Y, Tateo S, Mizutome H, Asatsuka-Okumura T, Shimizu N, Kishi T, Momose S, Kizuki M, et al. ARID2 is a pomalidomide-resistant, drug-resistant, and future. Drug Discov Today Technol. 2019;31(1):15–21.

99. Carayannopoulos L, Palmisano M. First-in-Human, Single- and Multiple-Dose Study of Iberdomide (CC-220) in Healthy Subjects. Eur J Clin Pharmacol. 2019;75(12):1637–49.
122. Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020;13(1):50.

123. He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, et al. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol. 2020;13(1):103.

124. Liu J, Ma J, Liu Y, Xia J, Li Y, Wang ZP, Wei W. PROTACs: A novel strategy for cancer therapy. Semin Cancer Biol. 2020;67(Pt 2):171–9.

125. Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J, Zhu H, Farley KA, Ding W, Schiemer J, et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A. 2018;115(31):E7285-E92.

126. Lai AC, Toure M, Hellenschmidt D, Salami J, Jaime-Figueroa S, Ko E, Hines J, Crews CM. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55(28):807–10.

127. Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376–81.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.